



MAHCX / X linked Disorders of Intracellular Cobalamin Metabolism



Intracellular B12 role & genes interaction with cblX



<u>Insight:</u>

- 1. What are the specific clinical characteristics of intracellular cobalamin metabolism disorders?
- 2. Can B12-related disease and its severity be diagnosed alone with laboratory tests without mutation testing?
- 3. Which NGS-based test will be ordered in the first place for case IV:3?
- 4. What are the genes related to extracellular B12 metabolism?
- 5. Is there any biomarker existing for disorders of Intracellular Cobalamin Metabolism?

Plausible tenets:

Gene: HCFC1 (Xq28); 24,805 bp & 26 Exons


- A member of the host cell factor family, a multiprotein-DNA complex as a global transcriptional coregulator
- Transcript (8,876 bps), 4 transcripts (splice variants), 157 orthologues & 10 paralogues; 69 domains and features
- Protein HCF-1 (2035 AA, 208732 D): a fibronectin-like motif, five *Kelch* repeats, & six *HCF* repeats (Cleavage sites)
- Help in the formation of cofactors for two cobalamin-dependent enzymes (MCM & MS) for whole animal kingdom
- A potent regulator of chromatin & embryonic neural development
- Cell cycle regulator (assists G1 to S phase shift), complex interact & moderate with various transcription factors as homeobox protein, FOXO3 & E2F1 (beta-cell growth) & chromatin modifier proteins (epigenetic regulation)

Clinical phenotypes: Simplified Genotype and Phenoty	pe relationship (MOI- X linked recessive)
Dla sus a travela	Complement UCE 1 anti-star / UCEC1 Complement

Phenotype	Genotype- HCF-1 activity/ HCFC1 Gene expression
Methylmalonic aciduria and homocystinemia	Absent
X-linked intellectual disability (variable severity)	Partial

- Other associated features: intractable epilepsy, hypotonia, microcephaly, choreoathetosis, & behavioral problems Management:

- **Investigation:** Evaluation of the methylmalonic acid (MMA) level in urine and blood and total plasma homocysteine (tHcy) level are the mainstays of biochemical testing.
- Complementation analysis cblC type, so need confirmatory testing by gene sequencing.
- Acute R: vital care, early intervention for thromboembolic & metabolic complications, retaining anabolic state
- **Long term** R: Decrease MMA, tHcy level & sustain normal concentrations of methionine in plasma & Injectable hydroxocobalamin (OHCbl) and betaine. Standard treatment for other symptoms as per protocol



Can YY1 and GABP mutations present like intracellular B12 pathway-related disorders?

Does antenatal B12 supplementation have any protective role on congenital malformation and non-syndromic intellectual deficiency?

Can HCFC1 expression inhibition be a novel therapy for viral encephalitis, primarily due to the Herpesviridae family?